ARS Pharmaceuticals Form 4: 50,000-share sale by CEO under 10b5-1 plan
Rhea-AI Filing Summary
ARS Pharmaceuticals insider transaction: Richard E. Lowenthal, President & CEO and director, reported the sale of 50,000 shares of ARS Pharmaceuticals (SPRY) on 08/21/2025 under a Rule 10b5-1 plan. The weighted average sale price was $14.4869, with individual trade prices ranging from $14.31 to $14.61.
The filing discloses that Lowenthal retains significant indirect holdings through trusts: 1,196,494 shares indirectly by a charitable remainder unitrust for which he is trustee, 1,247,447 shares indirectly by a unitrust for which his spouse is trustee, and 8,859,200 shares indirectly via the Lowenthal-Tanimoto Family Trust, for a combined substantial ownership position.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small, planned sale by CEO under a 10b5-1 plan; substantial indirect holdings remain intact.
The reported sale of 50,000 shares appears executed under a pre-existing Rule 10b5-1 plan, which signals pre-planned, compliant disposition rather than opportunistic trading. The amount sold represents a small fraction of the aggregate beneficial ownership disclosed, so there is no immediate evidence of a material change in insider alignment with shareholders. Price range and weighted-average price are provided, enhancing transparency.
TL;DR: Filing shows strong disclosure practices and concentrated insider ownership via trusts.
The Form 4 properly discloses relationship, trustee roles, and the nature of indirect ownership across multiple trusts. The reporting person disclaims direct beneficial ownership for certain trusts as appropriate. Continued high indirect ownership through family and charitable trusts indicates sustained insider economic interest, reducing governance concerns associated with a small sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 50,000 | $14.4869 | $724K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025. The weighted average sale price for the transaction reported was $14.4869 and the range of prices were between $14.31 and $14.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The Reporting Person is trustee of the trust. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The number of shares reported is comprised of (i) 1,098,499 shares that were previously reported as indirectly held by the Family Trust, (ii) 3,433,512 shares that were previously reported as indirectly held by the Reporting Person's spouse, and (iii) 4,327,189 shares that were previously reported as directly held by the Reporting Person. The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
